Abstract
Current concepts guiding the translation of oxytocin (OXT) neuroscience to the treatment of anxiety disorders and PTSD emphasize (i) identification of the neural targets of intranasal OXT, (ii) definition of the most effective dosage needed for target engagement, and (iii) comparison with clinically established traditional anxiolytics including lorazepam (LZP). In a series of functional MRI (fMRI) studies, each of these steps has been addressed, and the resulting data and implications thus provide the focus of this presentation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
